The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer
Official Title: Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer: a Comparative Randomized Phase II Trial
Study ID: NCT03777813
Brief Summary: This study aims to assess the efficacy of durvalumab in combination with radiochemotherapy (FOLFOX and IMRT) and then as maintenance therapy for treating patients with localised unresectable oesophageal cancer. This is a randomized, French national, multicentre, comparative phase II trial
Detailed Description: ARION study will randomize 120 patients, in 12 centers in France, according to a ratio 1:1 in the following arm of treatment: - Standard and experimental arm: Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of: * 50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET) * 45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node FOLFOX 4 simplified protocol, 1 infusion every 2 weeks (q2w) during 3 months starting with radiotherapy (+/- 1 day): * IV oxaliplatin 85 mg/m² in 2 h on day 1 (D1) * IV Leucovorin 200 mg/m² in 2 h on D1, followed by * IV 5-FU 400 mg/m² in 10 minutes on D1 followed by * IV continuous infusion 5-FU 2400 mg/m² in 46 h * Experimental arm: Concomitant administration of durvalumab: Every 4 weeks during concurrent FOLFOX (dose: 1500 mg) and after FOLFOX completion (total of 12 months of treatment).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Centre Oscar Lambret, CLCC UNICANCER, Lille, , France
Hôpital Saint Louis, APHP, Paris, , France
Hôpital Haut-Lévêque, Pessac, , France
Centre Hospitalier Universitaire, Poitiers, , France
Centre Paul Strauss, CLCC UNICANCER, Strasbourg, , France
Iuct, Clcc Unicancer, Toulouse, , France
CHU Rangueil Larrey, Toulouse, , France
Name: Anouchka Modesto, Doctor
Affiliation: Institut Claudius Regaud
Role: PRINCIPAL_INVESTIGATOR
Name: Laurent Quero, Doctor
Affiliation: Hôpital Saint Louis / Université Paris Diderot
Role: PRINCIPAL_INVESTIGATOR